Literature DB >> 18723958

Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice.

C S Vinodkumar1, Suneeta Kalsurmath, Y F Neelagund.   

Abstract

Drug resistance is the major cause of increase in morbidity and mortality in neonates. One thousand six hundred forty-seven suspected septicemic neonates were subjected for microbiological analysis over a period of 5 years. Forty-two P. aeruginosa were isolated and the antibiogram revealed that 28 P. aeruginosa were resistant to almost all the common drugs used (multidrug-resistant). The emergence of antibiotic-resistant bacterial strains is one of the most critical problems of modern medicine. As a result, a novel and most effective approaches for treating infection caused by multidrug-resistant bacteria are urgently required. In this context, one intriguing approach is to use bacteriophages (viruses that kill bacteria) in the treatment of infection caused by drug-resistant bacteria. In the present study, the utility of lytic bacteriophages to rescue septicemic mice with multidrug-resistant (MDR) P. aeruginosa infection was evaluated. MDR P. aeruginosa was used to induce septicemia in mice by intraperitoneal (i.p.) injection of 10(7) CFU. The resulting bacteremia was fatal within 48 hrs. The phage strain used in this study had lytic activity against a wide range of clinical isolates of MDR P. aeruginosa. A single i.p. injection of 3 x 10(9) PFU of the phage strain, administered 45 min after the bacterial challenge, was sufficient to rescue 100% of the animals. Even when treatment was delayed to the point where all animals were moribund, approximately 50% of them were rescued by a single injection of this phage preparation. The ability of this phage to rescue septicemic mice was demonstrated to be due to the functional capabilities of the phage and not to a nonspecific immune effect. The rescue of septicemic mice could be affected only by phage strains able to grow in vitro on the bacterial host used to infect the animals and when such strains are heat-inactivated, they lose their ability to rescue the infected mice. Multidrug-resistant bacteria have opened a second window for phage therapy. It would seem timely to begin to look afresh at this approach. A scientific methodology can make phage therapy as a stand-alone therapy for infections that are fully resistant to antibiotics.

Entities:  

Mesh:

Year:  2008        PMID: 18723958     DOI: 10.4103/0377-4929.42511

Source DB:  PubMed          Journal:  Indian J Pathol Microbiol        ISSN: 0377-4929            Impact factor:   0.740


  16 in total

Review 1.  Biological challenges of phage therapy and proposed solutions: a literature review.

Authors:  Katherine M Caflisch; Gina A Suh; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2019-12-02       Impact factor: 5.091

Review 2.  Insights into Bacteriophage Application in Controlling Vibrio Species.

Authors:  Vengadesh Letchumanan; Kok-Gan Chan; Priyia Pusparajah; Surasak Saokaew; Acharaporn Duangjai; Bey-Hing Goh; Nurul-Syakima Ab Mutalib; Learn-Han Lee
Journal:  Front Microbiol       Date:  2016-07-19       Impact factor: 5.640

3.  The Potential of Phage Therapy in Sepsis.

Authors:  Andrzej Górski; Ewa Jończyk-Matysiak; Marzanna Łusiak-Szelachowska; Ryszard Międzybrodzki; Beata Weber-Dąbrowska; Jan Borysowski
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

4.  Phage Inhibit Pathogen Dissemination by Targeting Bacterial Migrants in a Chronic Infection Model.

Authors:  Sophie E Darch; Kasper N Kragh; Evelyn A Abbott; Thomas Bjarnsholt; James J Bull; Marvin Whiteley
Journal:  mBio       Date:  2017-04-04       Impact factor: 7.867

Review 5.  Efficacy of φkm18p phage therapy in a murine model of extensively drug-resistant Acinetobacter baumannii infection.

Authors:  Jiun-Ling Wang; Chih-Feng Kuo; Che-Ming Yeh; Jung-Ren Chen; Ming-Fang Cheng; Chih-Hsin Hung
Journal:  Infect Drug Resist       Date:  2018-11-15       Impact factor: 4.003

6.  Identification and characterization of phage protein and its activity against two strains of multidrug-resistant Pseudomonas aeruginosa.

Authors:  Fairoz Al-Wrafy; Ewa Brzozowska; Sabina Górska; Marek Drab; Magdalena Strus; Andrzej Gamian
Journal:  Sci Rep       Date:  2019-09-17       Impact factor: 4.379

Review 7.  How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections.

Authors:  Majid Taati Moghadam; Nour Amirmozafari; Aref Shariati; Masoumeh Hallajzadeh; Shiva Mirkalantari; Amin Khoshbayan; Faramarz Masjedian Jazi
Journal:  Infect Drug Resist       Date:  2020-01-07       Impact factor: 4.003

8.  Isolation and characterization of φkm18p, a novel lytic phage with therapeutic potential against extensively drug resistant Acinetobacter baumannii.

Authors:  Gwan-Han Shen; Jiun-Ling Wang; Fu-Shyan Wen; Kai-Ming Chang; Chih-Feng Kuo; Chun-Hung Lin; Huei-Ru Luo; Chih-Hsin Hung
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

Review 9.  A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens.

Authors:  Xavier Wittebole; Sophie De Roock; Steven M Opal
Journal:  Virulence       Date:  2013-08-13       Impact factor: 5.882

10.  Explorative Study on Isolation and Characterization of a Microviridae G4 Bacteriophage, EMCL318, against Multi-Drug-resistant Escherichia coli 15-318.

Authors:  Soumya Ghosh; Emma Persad; Ting-Yun Shiue; Cindy Lam; Afsana Islam; Lauren G Mascibroda; Michael B Sherman; Thomas Smith; Naowarat Cheeptham
Journal:  Antibiotics (Basel)       Date:  2018-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.